Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Provided By GlobeNewswire
Last update: Oct 9, 2024
WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees.
